Day One price target lowered to $30 from $34 at JonesResearch

JonesResearch lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $30 from $34 and keeps a Buy rating on the shares following the Q4 report. The Ojemda launch is going as expected, and is now facing the harder-to-convert physicians following solid traction with early adopters, the analyst tells investors in a research note. The firm says its physician calls indicated that physicians would prefer to see at least one year of real world safety data before making the switch to Ojemda. Jones remains positive on Day One’s “steady growth.”